✦ LIBER ✦

Imatinib mesylate responsiveness in aggressive systemic mastocytosis: Novel association with a platelet derived growth factor receptor beta mutation

✍ Scribed by Bakul I. Dalal; Douglas E. Horsman; Hélène Bruyèrè; Donna L Forrest

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 251 KB
Volume: 82
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.20833

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 trial of imatinib mesylate in

A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β : An Italian Sarcoma Group study

✍ Giovanni Grignani; Emanuela Palmerini; Silvia Stacchiotti; Antonella Boglione; V 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 2 views

Microsatellites and intragenic polymorph

Microsatellites and intragenic polymorphisms of transforming growth factor β and platelet-derived growth factor and their receptor genes in Native Americans with systemic sclerosis (scleroderma): A preliminary analysis showing no genetic association

✍ Xiaodong Zhou; Filemon K. Tan; David N. Stivers; Frank C. Arnett 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 1 views

Imatinib mesylate for targeting the plat

Imatinib mesylate for targeting the platelet-derived growth factor β receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer—A dose-escalation Phase I trial

✍ Salah-Eddin Al-Batran; Akin Atmaca; Eberhard Schleyer; Claudia Pauligk; Christia 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

## Abstract ## BACKGROUND. In previous experimental models, because of its ability to inhibit the activity of platelet‐derived growth factor β receptor, imatinib decreased the interstitial fluid pressure and improved the delivery and efficacy of anticancer drugs, including fluorouracil. The object